Paving the way to precision medicine in multiple myeloma

Click to increase image sizeClick to decrease image size

Declaration of interest

S Harrison receives consultancy fees from, is on the advisory board for and an investigator for Abbvie; Celgene and Janssen; receives honoraria and research funding from Celgene and Janssen. J Ross has employment with AbbVie and may hold stock or other options. P Moreau receives consultancy and honoraria fees from Sanofi, Janssen, Amgen, Celgene/Bristol-Myers Squibb and Abbvie; honoraria from Takeda and Novartis. SK Kumar receives Research funding for clinical trials to the institution from Abbvie, Amgen, BMS, Carsgen, Janssen, KITE, Merck, Medimmune, Novartis, Roche-Genentech, Takeda, and Tenebio; is on the consulting/advisory board for (with no personal payments) Abbvie, Amgen, BMS, Janssen, Roche-Genentech, Takeda; and (with personal payment) Oncopeptides, Beigene. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.